Search research articles
Contact Us
Filters
Showing results (71-80 of 80) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 80 results.
BMC Cancer
|
October 23, 2019
Patient-derived organoids (PDOs) as a novel in vitro model for neuroblastoma tumours
P Fusco, B Parisatto, E Rampazzo, et al.
Oncogene
|
November 21, 2007
Isolation and functional assessment of common, polymorphic variants of the B-MYB proto-oncogene associated with a reduced cancer risk
R Schwab, R Bussolari, D Corvetta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 19, 2002
Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors
A Garaventa, L Boni, M S Lo Piccolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1997
MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children
G P Tonini, L Boni, A Pession, et al.
British Journal of Cancer
|
September 15, 2012
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project
G Schleiermacher, V Mosseri, W B London, et al.
Nature
|
August 30, 2008
Identification of ALK as a major familial neuroblastoma predisposition gene
Yaël P Mossé, Marci Laudenslager, Luca Longo, et al.
Molecular Cancer
|
June 10, 2008
Involvement of GTA protein NC2beta in neuroblastoma pathogenesis suggests that it physiologically participates in the regulation of cell proliferation
Cinzia Di Pietro, Marco Ragusa, Davide Barbagallo, et al.
British Journal of Cancer
|
October 31, 2014
Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification
R Defferrari, K Mazzocco, I M Ambros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2003
Quality assessment of genetic markers used for therapy stratification
I M Ambros, J Benard, M Boavida, et al.
British Journal of Cancer
|
December 8, 2011
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)
G Schleiermacher, J Michon, A Ribeiro, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 80) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 80 results.
BMC Cancer
|
October 23, 2019
Patient-derived organoids (PDOs) as a novel in vitro model for neuroblastoma tumours
P Fusco, B Parisatto, E Rampazzo, et al.
Oncogene
|
November 21, 2007
Isolation and functional assessment of common, polymorphic variants of the B-MYB proto-oncogene associated with a reduced cancer risk
R Schwab, R Bussolari, D Corvetta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 19, 2002
Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors
A Garaventa, L Boni, M S Lo Piccolo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1997
MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children
G P Tonini, L Boni, A Pession, et al.
British Journal of Cancer
|
September 15, 2012
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project
G Schleiermacher, V Mosseri, W B London, et al.
Nature
|
August 30, 2008
Identification of ALK as a major familial neuroblastoma predisposition gene
Yaël P Mossé, Marci Laudenslager, Luca Longo, et al.
Molecular Cancer
|
June 10, 2008
Involvement of GTA protein NC2beta in neuroblastoma pathogenesis suggests that it physiologically participates in the regulation of cell proliferation
Cinzia Di Pietro, Marco Ragusa, Davide Barbagallo, et al.
British Journal of Cancer
|
October 31, 2014
Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification
R Defferrari, K Mazzocco, I M Ambros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2003
Quality assessment of genetic markers used for therapy stratification
I M Ambros, J Benard, M Boavida, et al.
British Journal of Cancer
|
December 8, 2011
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)
G Schleiermacher, J Michon, A Ribeiro, et al.
Page
of 8